Top Markets
#1 DeFiChain DeFiChain +2,516.54%
#2 Akedo Akedo +216.88%
#3 ONFA ONFA +54.35%
#4 Metaplex Metaplex +22.47%
#5 Wrapped Krown Wrapped Krown +19.91%
#6 Talus Network Talus Network +19.16%
#7 Black Phoenix Black Phoenix +14.95%
#8 Magma Finance Magma Finance +14.91%
#9 DODO DODO +13.28%
#10 Gnosis Gnosis +12.20%
Coin of the day
DeFiChain DeFiChain
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Valbiotis SA Valbiotis SA

Valbiotis SA

ALVAL
Rang in Aktien #16324
Valbiotis SA engages in the research and development of health nutrition... Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
Aktienkurs
$0.94180721
Marktkapitalisierung
$22.26M
Veränderung (1 Tag)
0.38%
Veränderung (1 Jahr)
-14.35%
Land
FR
Handel Valbiotis SA (ALVAL)

Kategorie

Healthcare
Kursverlauf für Valbiotis SA (ALVAL)
Höchster Schlusskurs: $0.95 am 2026-07-01

Niedrigster Schlusskurs: $11.52 am 2017-06-01
Kursverlauf der Aktie von Valbiotis SA von 2017 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) -15.31%
2025 -7.34%
2024 -73.56%
2023 44.27%
2022 -51.96%
2021 6.16%
2020 207.03%
2019 -38.49%
2018 -47.84%
2017 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $49.07 -27.00%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $476.31 2.61%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $656.12 19.74%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $276.02 39.08%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $859.43 54.58%
NL